These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30922418)

  • 21. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.
    Merlin T; Farah C; Schubert C; Mitchell A; Hiller JE; Ryan P
    Med Decis Making; 2013 Apr; 33(3):333-42. PubMed ID: 22895559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effects of the New Methodology Application on the Method of Pricing of Drugs-The Case of the Republic of Macedonia.
    Zareski R; Kapedanovska Nestorovska A; Grozdanova A; Dimitrova B; Suturkova LJ; Sterjev Z
    Value Health Reg Issues; 2016 Sep; 10():19-28. PubMed ID: 27881273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals.
    Herr A; Suppliet M
    J Health Econ; 2017 Dec; 56():19-29. PubMed ID: 28964941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 29. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. If it ain't broke, don't price fix it: the OFT and the PPRS.
    Towse A
    Health Econ; 2007 Jul; 16(7):653-65. PubMed ID: 17595047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.
    Benisheva-Dimitrova T; Sidjimova D; Cherneva D; Kralimarkov N
    Int J Technol Assess Health Care; 2017 Jan; 33(3):365-370. PubMed ID: 28831942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority.
    Ali GK; Yahia Y
    East Mediterr Health J; 2012 Aug; 18(8):811-20. PubMed ID: 23057369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bitter pill to swallow: How price-hiking drug companies exploit the National Health Service.
    Kenber B
    Med Leg J; 2018 Sep; 86(3):123-131. PubMed ID: 29683051
    [No Abstract]   [Full Text] [Related]  

  • 36. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Policy in Greece.
    Yfantopoulos JN; Chantzaras A
    Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
    Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
    Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.